DC Archives | BioLife Solutions

Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine

Hardin, Vreeland, Clifton, Hale, Herbert, Greene, Jackson, Berry, Nichols, Yin, Yu, Wagner, Peoples. Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. Immunotherapy (2018) 10(5), 373–382. https://doi.org/10.2217/imt-2017-0114

Technology Transfer and Process Development for an Autologous Cell Therapy Against Multiple Sclerosis

GMP-Compliant Production Dendritic Cells

Improving Cryopreservation Yield

Designing a dendritic cell-based therapy for primary liver cancer

Curbishley SM, Blahava M, Adams DH. Designing a dendritic cell-based therapy for primary liver cancer. MACS&more, Vol 17-1/2016

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.

Podrazil M, Horvath R, Becht E, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. (2015). Oncotarget, 5, 17891-17904. DOI: 10.18632/oncotarget.4145

Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.

Eyrich M, et al. Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. Cytotherapy – July 2014 (Vol. 16, Issue 7, Pages 946-964, DOI: 10.1016/j.jcyt.2014.02.017).